Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood <i>WT1</i>‐mRNA expression in patients with AML and MDS

Abstract

PB WT1 expression represents a useful method to estimate pretransplant MRD, which is highly predictable for post-transplant outcome and may help improving peri-transplant management in AML/MDS patients.